Today Aerie Pharmaceuticals Inc (AERI) Stock Reaches All Time High

October 13, 2017 - By reb123z

Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.21, from 0.96 in 2017Q1. It increased, as 21 investors sold Aerie Pharmaceuticals Inc shares while 48 reduced holdings. 33 funds opened positions while 48 raised stakes. 31.61 million shares or 3.55% more from 30.53 million shares in 2017Q1 were reported.
Colony Ltd Limited Liability Company holds 5,370 shares or 0.02% of its portfolio. Tower Rech Ltd Liability (Trc) owns 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 237 shares. C World Wide Gp Hldg A S, a Denmark-based fund reported 89,549 shares. Voya Inv Mgmt Limited Com holds 0.04% in Aerie Pharmaceuticals Inc (NASDAQ:AERI) or 352,776 shares. Dekabank Deutsche Girozentrale reported 0.01% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). New York-based Alliancebernstein Limited Partnership has invested 0.02% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Jennison Assocs Limited Company owns 1.89M shares for 0.11% of their portfolio. Blackrock Inc holds 0.01% or 2.60M shares in its portfolio. Neuberger Berman Group Incorporated Ltd Liability Company has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Suffolk Mngmt Limited Liability Co owns 145,853 shares. Rhumbline Advisers accumulated 34,913 shares. Bankshares Of Ny Mellon accumulated 436,955 shares. Gsa Ptnrs Limited Liability Partnership reported 4,906 shares stake. Legal General Gru Public Ltd Company reported 7,534 shares stake. Wellington Gru Limited Liability Partnership accumulated 0.04% or 3.32M shares.

Since May 9, 2017, it had 1 buying transaction, and 1 sale for $1.08 million activity. The insider Cagle Gerald D. bought 1,000 shares worth $39,900.

The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) reached all time high today, Oct, 13 and still has $64.52 target or 5.00 % above today’s $61.45 share price. This indicates more upside for the $2.23B company. This technical setup was reported by Barchart.com. If the $64.52 PT is reached, the company will be worth $111.50M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock decreased 2.38% or $1.5 during the last trading session, reaching $61.45. About 1.27 million shares traded or 50.59% up from the average. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since October 13, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Investors wait Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report on November, 1. its quarterly earnings Wall Street analysts expect $-0.79 EPS, up $0.02 or 2.47 % from last year’s $-0.81 same quarter earnings. Aerie Pharmaceuticals Inc’s Wall Street analysts see -3.66 % EPS growth, taking into account the $-0.82 EPS reproted in the previous quarter,

Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage

Among 13 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 38 analyst reports since August 7, 2015 according to SRatingsIntel. Needham maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Thursday, September 15. Needham has “Buy” rating and $52 target. On Wednesday, August 16 the stock rating was maintained by Canaccord Genuity with “Buy”. JMP Securities maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Friday, September 22. JMP Securities has “Buy” rating and $68.0 target. Cantor Fitzgerald maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Thursday, July 20 with “Buy” rating. On Tuesday, December 20 the stock rating was reinitiated by Canaccord Genuity with “Buy”. The firm earned “Buy” rating on Tuesday, September 26 by Cowen & Co. The rating was initiated by Mizuho with “Buy” on Wednesday, September 6. On Thursday, September 15 the stock rating was maintained by RBC Capital Markets with “Outperform”. Cantor Fitzgerald maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Wednesday, October 11. Cantor Fitzgerald has “Buy” rating and $62.0 target. As per Thursday, October 5, the company rating was maintained by Cowen & Co.

More notable recent Aerie Pharmaceuticals Inc (NASDAQ:AERI) news were published by: Seekingalpha.com which released: “Aerie buys drug delivery technology from Envisia Therapeutics” on October 05, 2017, also Marketwatch.com with their article: “Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment” published on October 13, 2017, Seekingalpha.com published: “Biotech Analysis Central: Daily Pharma News – October 12, 2017” on October 12, 2017. More interesting news about Aerie Pharmaceuticals Inc (NASDAQ:AERI) were released by: Benzinga.com and their article: “Mid-Afternoon Market Update: Hudson Technologies Drops Amid Concerning …” published on October 11, 2017 as well as Nasdaq.com‘s news article titled: “Company Spotlight: Aerie Pharmaceuticals” with publication date: October 06, 2017.

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $2.23 billion. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It currently has negative earnings. The Company’s product candidates include Rhopressa 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.